Trade Bonus BioGroup Ltd. - BBIXF CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 0.21-1.44 |
| Average Volume (10 days) | 2.51M |
| Average Volume (3 months) | 105.72M |
| Market Cap | 249.94M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 1.17B |
| Revenue | N/A |
| EPS | -0.03 |
| Dividend (Yield %) | N/A |
| Beta | 2.10 |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
Bonus BioGroup Ltd. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | |||
| Total Operating Expense | 64.735 | 19.444 | 20.909 | 18.45 | 20.13 |
| Selling/General/Admin. Expenses, Total | 43.75 | 8.023 | 9.752 | 7.567 | 9.201 |
| Research & Development | 19.509 | 10.354 | 10.08 | 10.686 | 10.767 |
| Other Operating Expenses, Total | |||||
| Operating Income | -64.735 | -19.444 | -20.909 | -18.45 | -20.13 |
| Other, Net | -24.936 | -1.408 | -0.195 | -0.364 | -0.067 |
| Net Income Before Taxes | -90.076 | -22.021 | -22.24 | -18.735 | -20.197 |
| Net Income After Taxes | -90.076 | -22.021 | -22.24 | -18.735 | -20.197 |
| Net Income Before Extra. Items | -90.076 | -22.021 | -22.24 | -18.735 | -20.197 |
| Net Income | -90.076 | -22.021 | -22.24 | -18.735 | -20.197 |
| Income Available to Common Excl. Extra. Items | -90.076 | -22.021 | -22.24 | -18.735 | -20.197 |
| Income Available to Common Incl. Extra. Items | -90.076 | -22.021 | -22.24 | -18.735 | -20.197 |
| Diluted Net Income | -90.076 | -22.021 | -22.24 | -18.735 | -20.197 |
| Diluted Weighted Average Shares | 1154.06 | 998.981 | 841.467 | 811.497 | 808.995 |
| Diluted EPS Excluding Extraordinary Items | -0.07805 | -0.02204 | -0.02643 | -0.02309 | -0.02497 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.07805 | -0.02204 | -0.02643 | -0.02309 | -0.02497 |
| Depreciation / Amortization | 1.476 | 1.067 | 1.077 | 0.197 | 0.162 |
| Interest Income (Expense), Net Non-Operating | -0.405 | -1.169 | -1.136 | 0.079 |
| Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 8.269 | 9.259 | 9.579 | 9.571 | 10.375 |
| Selling/General/Admin. Expenses, Total | 3.679 | 3.745 | 3.645 | 4.117 | 3.635 |
| Research & Development | 4.59 | 5.514 | 5.934 | 5.454 | 6.74 |
| Operating Income | -8.269 | -9.259 | -9.579 | -9.571 | -10.375 |
| Interest Income (Expense), Net Non-Operating | 0.345 | 4.647 | 2.506 | -0.463 | -0.005 |
| Other, Net | -8.176 | -0.681 | -0.231 | -5.973 | -1.148 |
| Net Income Before Taxes | -16.1 | -5.293 | -7.304 | -16.007 | -11.528 |
| Net Income After Taxes | -16.1 | -5.293 | -7.304 | -16.007 | -11.528 |
| Net Income Before Extra. Items | -16.1 | -5.293 | -7.304 | -16.007 | -11.528 |
| Net Income | -16.1 | -5.293 | -7.304 | -16.007 | -11.528 |
| Income Available to Common Excl. Extra. Items | -16.1 | -5.293 | -7.304 | -16.007 | -11.528 |
| Income Available to Common Incl. Extra. Items | -16.1 | -5.293 | -7.304 | -16.007 | -11.528 |
| Diluted Net Income | -16.1 | -5.293 | -7.304 | -16.007 | -11.528 |
| Diluted Weighted Average Shares | 1167.93 | 1167.93 | 1167.93 | 1155.96 | 1153.42 |
| Diluted EPS Excluding Extraordinary Items | -0.01379 | -0.00453 | -0.00625 | -0.01385 | -0.00999 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.01379 | -0.00453 | -0.00625 | -0.01385 | -0.00999 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Current Assets | 81.001 | 16.737 | 0.308 | 9.088 | 4.651 |
| Cash and Short Term Investments | 79.55 | 16.086 | 0.105 | 8.641 | 2.725 |
| Cash & Equivalents | 79.55 | 16.086 | 0.105 | 8.641 | 2.725 |
| Total Receivables, Net | 1.155 | 0.41 | 0.102 | 0.424 | 1.88 |
| Accounts Receivable - Trade, Net | |||||
| Other Current Assets, Total | |||||
| Total Assets | 104.322 | 51.437 | 6.99 | 10.158 | 5.577 |
| Property/Plant/Equipment, Total - Net | 14.961 | 5.726 | 6.585 | 0.973 | 0.824 |
| Intangibles, Net | 0.005 | ||||
| Other Long Term Assets, Total | 0.464 | 0.097 | 0.097 | 0.097 | 0.097 |
| Total Current Liabilities | 8.771 | 16.374 | 15.545 | 12.45 | 11.961 |
| Accounts Payable | 3.994 | 1.559 | 1.48 | 1.221 | 1.047 |
| Payable/Accrued | |||||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.118 | 11.185 | 9.362 | 8.275 | 7.273 |
| Total Liabilities | 19.892 | 20.753 | 20.711 | 13.335 | 11.961 |
| Total Long Term Debt | 11.121 | 4.379 | 5.166 | 0 | 0 |
| Total Equity | 84.43 | 30.684 | -13.721 | -3.177 | -6.384 |
| Common Stock | 296.524 | 156.654 | 85.011 | 68.757 | 65.133 |
| Retained Earnings (Accumulated Deficit) | -212.094 | -125.97 | -105.346 | -87.731 | -71.517 |
| Other Equity, Total | 0 | 6.614 | 15.797 | 0 | |
| Total Liabilities & Shareholders’ Equity | 104.322 | 51.437 | 6.99 | 10.158 | 5.577 |
| Total Common Shares Outstanding | 1154.06 | 998.981 | 841.467 | 811.497 | 808.995 |
| Prepaid Expenses | 0.296 | 0.241 | 0.101 | 0.023 | 0.046 |
| Property/Plant/Equipment, Total - Gross | 20.455 | 9.762 | 9.575 | 2.886 | 2.538 |
| Accumulated Depreciation, Total | -5.494 | -4.036 | -2.99 | -1.913 | -1.714 |
| Accrued Expenses | 2.43 | 2.855 | 3.993 | 2.954 | 3.641 |
| Other Liabilities, Total | 0.885 | ||||
| Long Term Investments | 7.896 | 28.877 | 0 | ||
| Current Port. of LT Debt/Capital Leases | 1.229 | 0.775 | 0.71 | ||
| Capital Lease Obligations | 11.121 | 4.379 | 5.166 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 78.283 | 81.001 | 92.565 | 82.69 | 92.77 |
| Cash and Short Term Investments | 71.95 | 79.55 | 91.467 | 81.257 | 88.778 |
| Cash & Equivalents | 71.95 | 79.55 | 91.467 | 81.257 | 88.778 |
| Total Receivables, Net | 6.333 | 1.451 | 1.098 | 1.433 | 3.992 |
| Accounts Receivable - Trade, Net | 6.333 | 1.451 | 1.098 | 1.433 | 3.992 |
| Total Assets | 105.758 | 104.322 | 117.112 | 96.567 | 118.308 |
| Property/Plant/Equipment, Total - Net | 18.518 | 14.961 | 12.649 | 1.752 | 5.87 |
| Long Term Investments | 8.493 | 7.896 | 11.434 | 11.661 | 19.571 |
| Other Long Term Assets, Total | 0.464 | 0.464 | 0.464 | 0.464 | 0.097 |
| Total Current Liabilities | 7.859 | 8.771 | 8.409 | 5.385 | 13.358 |
| Accounts Payable | 3.721 | 3.994 | 3.124 | 1.916 | 2.211 |
| Payable/Accrued | 2.869 | 2.494 | 2.972 | 2.119 | 5.231 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.243 | 1.229 | 1.477 | 0.31 | 0.798 |
| Other Current Liabilities, Total | 0.026 | 1.054 | 0.836 | 1.04 | 5.118 |
| Total Liabilities | 18.742 | 19.892 | 19.7 | 5.385 | 17.518 |
| Total Long Term Debt | 10.883 | 11.121 | 11.291 | 0 | 4.16 |
| Capital Lease Obligations | 10.883 | 11.121 | 11.291 | 0 | 4.16 |
| Total Equity | 87.016 | 84.43 | 97.412 | 91.182 | 100.79 |
| Common Stock | 307.606 | 296.524 | 295.909 | 241.537 | 204.652 |
| Retained Earnings (Accumulated Deficit) | -220.59 | -212.094 | -198.497 | -163.729 | -148.104 |
| Other Equity, Total | 0 | 0 | 13.374 | 44.242 | |
| Total Liabilities & Shareholders’ Equity | 105.758 | 104.322 | 117.112 | 96.567 | 118.308 |
| Total Common Shares Outstanding | 1167.93 | 1154.06 | 1153.42 | 1069.13 | 1067.15 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -90.076 | -22.021 | -22.24 | -18.735 | -20.197 |
| Cash From Operating Activities | -39.839 | -15.746 | -13.113 | -13.427 | -11.823 |
| Cash From Operating Activities | 1.476 | 1.067 | 1.077 | 0.197 | 0.163 |
| Non-Cash Items | 57.174 | 4.89 | 5.673 | 3.143 | 7.76 |
| Changes in Working Capital | -8.413 | 0.318 | 2.377 | 1.968 | 0.451 |
| Cash From Investing Activities | -6.176 | -0.254 | -0.187 | -0.341 | -0.269 |
| Capital Expenditures | -5.809 | -0.254 | -0.187 | -0.341 | -0.269 |
| Other Investing Cash Flow Items, Total | -0.367 | 0 | 0 | ||
| Cash From Financing Activities | 113.418 | 31.921 | 4.918 | 19.559 | 13.416 |
| Financing Cash Flow Items | 0 | 0 | 5.435 | 16.424 | 0 |
| Issuance (Retirement) of Stock, Net | 18.216 | 0.132 | 0.146 | 0.909 | 0.92 |
| Issuance (Retirement) of Debt, Net | 95.202 | 31.789 | -0.663 | 2.226 | 12.496 |
| Net Change in Cash | 63.464 | 15.981 | -8.536 | 5.916 | 1.324 |
| Foreign Exchange Effects | -3.939 | 0.06 | -0.154 | 0.125 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.304 | -90.076 | -74.069 | -62.541 | -44.958 |
| Cash From Operating Activities | -8.254 | -39.839 | -33.442 | -28.644 | -19.798 |
| Cash From Operating Activities | 0.542 | 1.476 | 0.905 | 0.402 | 0.281 |
| Non-Cash Items | -0.171 | 57.174 | 48.25 | 44.179 | 32.52 |
| Changes in Working Capital | -1.321 | -8.413 | -8.528 | -10.684 | -7.641 |
| Cash From Investing Activities | -4.075 | -6.176 | -3.391 | -1.237 | -0.445 |
| Capital Expenditures | -4.075 | -5.809 | -3.024 | -0.87 | -0.445 |
| Cash From Financing Activities | 2.816 | 113.418 | 113.478 | 95.613 | 91.829 |
| Financing Cash Flow Items | 0 | 0 | 0 | 13.374 | 45.942 |
| Issuance (Retirement) of Stock, Net | 3.058 | 18.216 | 17.765 | 2.879 | 2.712 |
| Issuance (Retirement) of Debt, Net | -0.242 | 95.202 | 95.713 | 79.36 | 43.175 |
| Foreign Exchange Effects | 1.913 | -3.939 | -1.264 | -0.561 | 1.106 |
| Net Change in Cash | -7.6 | 63.464 | 75.381 | 65.171 | 72.692 |
| Other Investing Cash Flow Items, Total | 0 | -0.367 | -0.367 | -0.367 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Meretzki (Shai) | Individual Investor | 32.966 | 385017966 | 5551455 | 2022-12-28 | |
| Rauch (Yosef) | Individual Investor | 11.383 | 132945004 | 875000 | 2022-12-28 | |
| Shapira (Gil) | Individual Investor | 0.6085 | 7106418 | 0 | 2022-12-28 | |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1 | 1167456 | 19019 | 2023-02-28 | LOW |
| Reznick (Yehuda) | Individual Investor | 0.0626 | 730797 | 0 | 2022-12-28 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Bonus BioGroup Ltd. Company profile
About Bonus Biogroup Ltd
Bonus Biogroup Ltd, formerly Oceana Advanced Industries Ltd, is an Israel-based product-focused biotechnology company applying technology for supplying bone regeneration tissues. The Company is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. It is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Bonus Biogroup Ltd revenues was not reported. Net loss increased from NIS14.5M to NIS74.1M. Higher net loss reflects General & Administrative Expenses increase from NIS5.2M to NIS39.8M (expense), Research Expenses increase of 85% to NIS15.3M (expense), Financing Income decrease of 6% to NIS1.2M (income). Basic Earnings per Share excluding Extraordinary Items decreased from -NIS0.02 to -NIS0.07.
Equity composition
6/2012, 1-for-10 reverse stock split (Factor: 0.1).
| Industry: | Bio Medical Devices |
פארק מת"מ 8ב'
3190501
Income Statement
- Annual
- Quarterly
News
GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023
Shiba Inu price prediction: Can the meme coin build on recent gains?
What’s next for the Shiba Inu meme coin after a sluggish 2022 so far? Read more…
12:51, 24 March 2023
Who are the biggest bitcoin mining companies?
Bitcoin mining is big business, but who are the biggest bitcoin mining companies?
12:06, 24 March 2023
USD/PKR forecast: Will Pakistan’s rupee continue to fall?
The rupee has rebounded against the dollar in recent months, will this trend continue?
11:49, 24 March 2023
Amazon stock forecast: Where next for AMZN amid massive layoffs?
Amazon has been making tens of thousands of its workers redundant. Does this affect the market’s baseline Amazon stock forecast?
10:46, 24 March 2023
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com